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Randomized phase 3 evaluation of
trifarotene 50 mg/g cream treatment of
moderate facial and truncal acne
Jerry Tan, MD,a Diane Thiboutot, MD,b Georg Popp, MD,c Melinda Gooderham, MD,d Charles Lynde, MD,e
James Del Rosso, DO,f Jonathan Weiss, MD,g Ulrike Blume-Peytavi, MD,h Jolanta Weglovska, MD,i
Sandra Johnson, MD,j Lawrence Parish, MD,k Dagmara Witkowska, MD,l Nestor Sanchez Colon, MD,m
Alessandra Ali
o Saenz, MD,n Faiz Ahmad, MS,n Michael Graeber, MD,n and Linda Stein Gold, MDo
Windsor, Peterborough, and Markham, Ontario, Canada; Hershey and Philadelphia, Pennsylvania;
Augsburg and Berlin, Germany; Las Vegas, Nevada; Snellville Georgia; Wrocław, Poland; Fort Smith,
Arkansas; San Juan, Puerto Rico; Fort Worth Texas; and Detroit, Michigan
Background: Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial
acne has not been rigorously studied.
Objectives: Assess the safety and efficacy of trifarotene 50 g/g cream, a novel topical retinoid, in
moderate facial and truncal acne.
Methods: Two phase III double-blind, randomized, vehicle-controlled, 12-week studies of once-daily
trifarotene cream versus vehicle in subjects aged 9 years or older. The primary end points were rate of
success on the face, as determined by the Investigator’s Global Assessment (clear or almost clear and $2grade improvement), and absolute change from baseline in inflammatory and noninflammatory counts
from baseline to week 12. The secondary end points were rate of success on the trunk (clear or almost clear
and $2-grade improvement) and absolute change in truncal inflammatory and noninflammatory counts
from baseline to week 12. Safety was assessed through adverse events, local tolerability, vital signs, and
routine laboratory testing results.
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Results: In both studies, at week 12 the facial success rates according to the Investigator’s Global
Assessment and truncal Physician’s Global Assessment and change in inflammatory and noninflammatory
lesion counts (both absolute and percentage) were all highly significant (P \ .001) in favor of trifarotene
when compared with the vehicle.
Limitations: Adjunctive topical or systemic treatments were not studied.
Conclusion: These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in
treatment of both facial and truncal acne. ( J Am Acad Dermatol 2019;80:1691-9.)
Key words: acne vulgaris; phase 3 trial; pivotal trials; trifarotene; truncal acne.

Acne vulgaris (AV) is one
were 12-week, doubleof the most common skin
blinded, multicenter, and
CAPSULE SUMMARY
diseases, and it has a multivehicle controlled, with a
factorial pathogenesis that
1:1 randomization pattern
Trifarotene is a new retinoic acid
centers on pilosebaceous
(once-daily
trifarotene
receptor gamma-geselective topical
units.1,2 Because the patho50 g/g or vehicle cream).
retinoid cream formulation that is
physiology and clinical preRandomization was stratified
suitable for use on the face and trunk.
sentations of facial and
by study center with use of
Trifarotene appears to be safe and
truncal acne are considered
an interactive response techefficacious as treatment of moderate
to be similar, clinicians often
nology system. The clinical
acne on the face and trunk. Local
apply the same therapeutic
study was conducted accordtolerability was acceptable and
approach for facial and noning to standard recognized
manageable on the face and trunk.
facial lesions despite a lack of
practices, as detailed in the
evidence in truncal AV.3-5 A
Supplemental
Information
variety of treatment options
(additional details about the
are currently available for AV, but they have not been
methods and a complete disposition chart are availrigorously studied in truncal disease.
able at http://dx.doi.org/10.17632/cfjst82z93.1).
Trifarotene 50 g/g cream is a new selective
Instruction was provided to all patients or careretinoic acid receptor (RAR)-g (RARg) topical retigivers about how to apply a thin layer of the study
noid and is unique in that its clinical development
drug daily at bedtime on the face and self-reachable
program included evaluation of performance in both
trunk, including areas with no clinically evident
moderate facial and truncal acne. The selectivity of
acne. Patients were also instructed to cleanse the
trifarotene for RARg distinguishes it from the existing
skin and not apply moisturizer 1 hour before or
first- and third-generation topical retinoids, which
1 hour after application of the study drug. Use of
target both RARb and RARg.6 Trifarotene is pharmamoisturizer was encouraged from the initiation of
treatment. Investigators could reduce the frequency
cokinetically stable in keratinocytes but is rapidly
of application to alternate days for a maximum of
metabolized in hepatic microsomes, predicting a
2 weeks in the first 4 weeks following the baseline
favorable safety profile; in addition, it has comedovisit, when needed to manage irritation.
lytic, anti-inflammatory, and antipigmenting
properties. The primary efficacy results from 2
large-scale phase III studies (PERFECT 1 and
Study participants
PERFECT 2 ClinicalTrials.gov registration number
The eligibility criteria were patient age 9 years and
NCT02566369 and NCT02556788, respectively, and
older, moderate facial acne (defined as an
European Clinical Trials Database numbers 2016Investigator’s Global Assessment [IGA] score of 3
002860-15 and 2016-002540-13, respectively]) are
on the face [$20 inflammatory lesions and $25
reported here.
noninflammatory lesions]), and moderate truncal
acne (defined as a Physician’s Global Assessment
[PGA] score of 3 at screening and baseline [$20
METHODS
inflammatory lesions and 20 to \100 noninflammaStudy design
tory lesions on the areas of the trunk reachable for
PERFECT 1 and PERFECT 2 were identical in
self-application]). Accessible treated areas of the
design and conducted in the United States, Canada,
trunk were defined for the study. The trunk anatomic
Europe, and Russia from 2015 to 2017. Both studies
d

d
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Abbreviations used:
AE:
AV:
IGA:
PGA:
RAR:
RARg:
TEAE:

adverse event
acne vulgaris
Investigator’s Global Assessment (facial
acne)
Physician’s Global Assessment (truncal
acne)
retinoic acid receptor
retinoic acid receptor-g
treatment-emergent adverse event

region assessment was predefined by a size-fitted Tshirt (patent No. US00D758048S [approved June 7,
2016]). This ensured consistency for study assessment areas throughout the study duration. For subjects aged 9 to 11 years, the inclusion criteria
regarding truncal acne were optional owing to the
relative rarity of truncal involvement (compared with
facial involvement) in this age group.
The exclusion criteria were severe forms of acne;
more than 1 nodule on the face; more than 1 nodule
on the trunk; presence of acne cysts, beard, or facial
hair that could interfere with study assessments;
presence of tattoos that could interfere with study
assessments; uncontrolled or serious disease or
medical condition; clinically significant abnormal
laboratory values; known or suspected allergies or
sensitivities to the planned study drugs; and lactation
or intent to conceive during the study in women. In
addition, prohibited medication use and washout
periods of 1 to 4 weeks were specified for use of
antiacne treatments (prescription and over-thecounter), nonsteroidal anti-inflammatory drugs, corticosteroids, and antibiotics (but 6 months for use of
oral retinoids and immunomodulators).
Efficacy and safety assessments
The 3 coprimary efficacy end points were rate of
success, as determined according to the IGA
(defined as the percentage of subjects who achieved
an IGA face rating of clear [0] or almost clear [1]) and
at least a 2-grade change from baseline) at week 12;
the absolute change in facial inflammatory lesion
count; and the absolute change in noninflammatory
lesion count from baseline to week 12. There were
also 3 secondary efficacy end points: rate of success,
as determined according to the PGA (defined as
percentage of subjects achieving a rating of clear or
almost clear on and at least a 2-grade change from
baseline) at week 12; absolute change in truncal
inflammatory lesion count from baseline to week 12;
and absolute change in truncal noninflammatory
lesion count from baseline to week 12. The definitions of severity for the IGA and PGA scales (5-point
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scales ranging from 0 [clear] to 4 [severe]) were the
same.
Lesion counts were performed, and IGA and PGA
scores were assessed at screening; at baseline; and at
the week 1, 2, 4, 8, and 12/early termination visits.
The safety assessments included treatmentemergent adverse events (TEAEs); standard laboratory safety test results at screening; and results at the
last study visit, including the following: hematology,
blood chemistry, and urinalysis results (BARC
Central Laboratory, Lake Success, NY, and Gent,
Belgium); physical examination findings; and monitoring of vital signs. Local tolerability signs and
symptoms expected with a topical retinoid were
collected separately from adverse events (AEs) to
better characterize the tolerability profile of trifarotene cream. These included erythema, scaling, dryness, and stinging/burning, which were scored on a
4-point scale (according to which a score of 0 indicated none, 1 indicated mild, 2 indicated moderate,
and 3 indicated severe). Subjects were specifically
queried at each study visit, including at baseline, for
the presence of local signs or symptoms. Signs and/
or symptoms of local cutaneous irritation assessed
with the tolerability scale were considered to be AEs
if they were severe enough to lead to permanent
discontinuation of treatment with the study product
or if they required use of concomitant treatment
(including over-the-counter products other than
moisturizers).
Statistical analysis
All efficacy end points, local tolerability, laboratory test results, and vital signs were summarized by
analysis visit. Categoric data were summarized by
frequency and percentage for each response category, and the continuous data were summarized by
using means, medians, minimums, maximums, and
standard deviations. For composite end points, success rates were analyzed via the Cochran-MantelHaenszel methodology stratified by analysis center.
Changes in lesion counts were evaluated through
analysis of covariance using baseline counts, analysis
center, and treatment as factors. The same statistical
methods were used for the composite secondary end
points. Multiple imputation methodology was used
for missing values.
TEAEs, regardless of relationship to study medication, were tabulated and summarized by incidence
as application site or noneapplication site events.
Relationship to treatment was determined by the
investigator. Common AEs were defined as those
experienced by at least 1% of all patients. Laboratory
evaluations were summarized with the use of
descriptive statistics.
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Table I. Patient characteristics (intent-to-treat population)
PERFECT 1
Characteristic

Trifarotene
50 mg/g (n = 612)

Age, y
n
612
Mean (SD)
19.6 6 6.88
Median
17
(Min, max)
(9, 58)
Age categories, n (%)
\18 y
314 (51.3)
$18 y
298 (48.7)
Sex, n (%)
Male
307 (50.2)
Female
305 (49.8)
Race, n (%)
White
508 (83.0)
Black or African American
47 (7.7)
Asian
23 (3.8)
American Indian or Alaska
11 (1.8)
Native
Native Hawaiian or other
1 (0.2)
Pacific Islander
Multiple
8 (1.3)
Other
14 (2.3)
Ethnicity, n (%)
Hispanic or Latino
135 (22.1)
Not Hispanic or Latino
477 (77.9)
Skin phototype, n (%)
Type I
31 (5.1)
Type II
197 (32.2)
Type III
233 (38.1)
Type IV
97 (15.8)
Type V
43 (7.0)
Type VI
11 (1.8)
Baseline disease characteristics, mean 6 SD
Facial inflammatory lesions
34.7 6 13.02
Facial noninflammatory
54.0 6 28.55
lesions
Trunk inflammatory lesions
36.9 6 17.89
Trunk noninflammatory
46.4 6 21.57
lesions

PERFECT 2

Vehicle
(n = 596)

Overall
(N = 1208)

Trifarotene
50 mg/g (n = 602)

Vehicle
(n = 610)

Overall
(N = 1212)

596
19.3 6 5.89
18
(10, 50)

1208
19.4 6 6.41
18
(9, 58)

602
19.6 6 6.2
18
(11.0, 49.0)

610
19.9 6 6.4
18
(11.0, 46.0)

1212
19.7 6 6.3
18
(11.0, 49.0)

278 (46.6)
318 (53.4)

592 (49.0)
616 (51.0)

276 (45.8)
326 (54.2)

294 (48.2)
316 (51.8)

570 (47.0)
642 (53.0)

272 (45.6)
324 (54.4)

579 (47.9)
629 (52.1)

245 (40.7)
357 (59.3)

272 (44.6)
338 (55.4)

517 (42.7)
695 (57.3)

484
49
32
5

992
96
55
16

565
27
2
1

554
42
6
2

(81.2)
(8.2)
(5.4)
(0.8)

(82.1)
(7.9)
(4.6)
(1.3)

(93.9)
(4.5)
(0.3)
(0.2)

(90.8)
(6.9)
(1.0)
(0.3)

1119
69
8
3

(92.3)
(5.7)
(0.7)
(0.2)

1 (0.2)

2 (0.2)

0 (0.0)

1 (0.2)

1 (0.1)

10 (1.7)
15 (2.5)

18 (1.5)
29 (2.4)

2 (0.3)
5 (0.8)

2 (0.3)
3 (0.5)

4 (0.3)
8 (0.7)

148 (24.8)
448 (75.2)

283 (23.4)
925 (76.6)

60 (10.0)
542 (90.0)

62 (10.2)
548 (89.8)

34
182
227
91
48
14

65
379
460
188
91
25

36
274
233
33
14
12

37
249
248
38
19
19

(5.7)
(30.5)
(38.1)
(15.3)
(8.1)
(2.3)

(5.4)
(31.4)
(38.1)
(15.6)
(7.5)
(2.1)

(6.0)
(45.5)
(38.7)
(5.5)
(2.3)
(2.0)

(6.1)
(40.8)
(40.7)
(6.2)
(3.1)
(3.1)

122 (10.1)
1090 (89.9)
73
523
481
71
33
31

(6.0)
(43.2)
(39.7)
(5.9)
(2.7)
(2.6)

34.8 6 13.612 34.8 6 13.31
52.8 6 26.08 53.4 6 27.35

36.1 6 12.47
50.6 6 25.93

37.1 6 15.06 36.6 6 13.84
51.2 6 25.75 50.9 6 25.83

35.6 6 16.70 35.3 6 17.32
47.5 6 21.94 46.9 6 21.75

39.0 6 16.16
46.1 6 20.17

39.1 6 17.41 39.1 6 16.80
45.7 6 19.58 45.9 6 19.87

SD, Standard deviation.

RESULTS
Subject disposition, demographics, and
baseline characteristics
In PERFECT 1, a total of 1524 subjects were
screened and 1208 were randomized; of the randomized subjects, 612 received trifarotene cream
and 596 received vehicle. There were 72 discontinuations in the trifarotene arm and 61 in the vehicle
arm, and in both cases the discontinuations were
primarily due to withdrawal by the subject and loss
to follow-up. In PERFECT 2, a total of 1293 subjects

were screened and 1212 were randomized; of the
randomized subjects, 602 received trifarotene cream
and 610 received vehicle. There were 44 discontinuations in the trifarotene arm and 37 in the vehicle
arm, and in both cases they were primarily due to
withdrawal by the subject and loss to follow-up.
Demographic and baseline data are presented in
Table I. The treatment groups were similar, with an
even distribution of pediatric and adult subjects, no
significant sex differences, and primarily white subjects with skin phototypes I to III.
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Table II. Summary efficacy results
PERFECT 1

Face: Coprimary end points

IGA success
Inflammatory lesions
Mean absolute change from baseline
Mean % change from baseline
Noninflammatory lesions
Mean absolute change from baseline
Mean % change from baseline

PERFECT 2

Trifarotene cream

Vehicle cream

Trifarotene cream

Vehicle cream

(n = 612)

(n = 596)

(n = 602)

(n = 610)

29.4%*

19.5%

42.3%*

25.7%

19.0*
54.4%*

15.4
44.8%

24.2*
66.2%*

18.7
51.2%

25.0*
49.7%*

17.9
35.7%

30.1*
57.7%*

21.6
43.9%

PERFECT 1

Trunk: secondary end points

PGA success
Inflammatory lesions
Mean absolute change from baseline
Mean % change from baseline
Noninflammatory lesions
Mean absolute change from baseline
Mean % change from baseline

PERFECT 2

Trifarotene cream

Vehicle cream

Trifarotene cream

Vehicle cream

(n = 600)

(n = 585)

(n = 598)

(n = 609)

35.7%*

25.0%

42.6%*

29.9%

21.4*
57.4%*

18.8
50.0%

25.5*
65.4%*

19.8
51.1%

21.9*
49.1%*

17.8
40.3%

25.9*
55.2%*

20.8
45.1%

Intent-to-treat, multiple imputation; success defined as at least a 2-grade improvement and IGA/PGA rating of clear (0) or almost clear (1).
IGA, Investigator’s Global Assessment; PGA, Physician’s Global Assessment.
*P less than .001 versus vehicle cream.

Efficacy
The results of all coprimary and cosecondary
efficacy assessments in both studies at week 12
were statistically significant (P \ .001) in favor of
trifarotene versus vehicle (Table II).
For the 1214 patients treated with trifarotene and
1206 treated with vehicle, the week 12 facial success rates according to the IGA were 29.4% in
PERFECT 1 and 42.3% in PERFECT 2 (vs 19.5% and
25.7% for vehicle [P \ .001]); trifarotene had statistically significant superior success rates at week 4
(PERFECT 1) and week 8 (PERFECT 2). Trifarotene
treatment achieved significantly superior reductions
in facial lesion counts as well, with statistical
differences apparent as early as weeks 2 and 1:
with trifarotene treatment, the mean absolute inflammatory lesion counts were reduced by19.0 and
24.2 (vs by 15.4 and 18.7 with vehicle [P \ .001])
and the mean absolute noninflammatory lesion
counts were reduced by 25.0 and 30.1 (vs by 17.9
and 21.6 with vehicle [P \ .001]). The 3 coprimary
end points from baseline to week 12 are shown in
Figure 1.
The secondary end points showing the treatment
effect on truncal acne from baseline to week 12 are
presented in Figure 2. At week 12, the rates of
success with trifarotene according to the truncal
PGA were 35.7% in PERFECT 1 and 42.6% in
PERFECT 2 (vs 25.0% and 29.9%, respectively for

vehicle [each P \.001]). In both PERFECT 1 and 2,
trifarotene was statistically significantly superior in
achieving reductions in inflammatory and noninflammatory lesions on the trunk starting by week 4
in PERFECT 1 and by week 2 in PERFECT 2. Rates of
success on the trunk were statistically significant for
trifarotene versus for vehicle starting at week 8 in
both studies.

Safety
Local tolerability. Local irritation related to
trifarotene cream was transient and consistent with
the known pattern of topical retinoid dermatitis (Fig
3); tolerability was better on the trunk than on the
face. Local tolerability signs and symptoms related to
trifarotene cream included erythema, scaling, dryness, and stinging/burning. These were mostly mild
to moderate by investigator assessment, with few
being severe. For facial acne, a worst postbaseline
score of moderate local tolerability signs and symptoms compared with baseline was reported for up to
33.2% of patients (in PERFECT 1: erythema, 23.7%;
scaling, 21.4%; dryness, 23.0%; and stinging/
burning, 16.3%; in PERFECT 2: erythema, 33.2%;
scaling, 32.9%; dryness, 36.4%; and stinging/
burning, 24.9%) and severe for up to 10.0% of
patients (in PERFECT 1: erythema, 2.5%; scaling,
2.9%; dryness, 2.5%; and stinging/burning, 4.2%; in
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Fig 1. Facial acne vulgaris: coprimary end point from baseline to week 12. Success according
to the facial Investigator’s Global Assessment (IGA) is defined as clear or almost clear and at
least a 2-grade improvement (intent-to-treat population; multiple imputation [MI]).

PERFECT 2: erythema, 10.0%; scaling, 6.8%; dryness,
7.1%; and stinging/burning, 7.6%). On the trunk, the
corresponding percentages of worst postbaseline
local tolerability signs and symptoms were moderate
for up to 23.2% of patients (in PERFECT 1: erythema,
14.6%; scaling, 10.8%; dryness, 11.3%; and stinging/
burning, 9.0%; in PERFECT 2: erythema, 23.2%;
scaling, 16.7%; dryness, 20.9%; and stinging/
burning, 12.9%) and severe for up to 7.2% of patients
(in PERFECT 1: erythema, 3.3%; scaling, 0.3%; dryness, 1.2%; and stinging/burning, 3.0%; in PERFECT
2: erythema, 7.2%; scaling, 3.0%; dryness, 2.5%; and
stinging/burning, 5.7%). The scores reached
maximum severity at week 1 for the face and at
weeks 2 to 4 on the trunk; after these time points,
scores diminished.
AEs. Most TEAEs related to trifarotene were
cutaneous and occurred at the application site.
Severe AEs considered related to trifarotene therapy
were reported in 6 subjects (in PERFECT 1: 4 with
skin irritation, 1 with sunburn, and 1 with allergic

dermatitis) and 3 subjects (in PERFECT 2: 1 with
application site pain, 1 with application site erosion,
and 1 with application site irritation) versus none in
the vehicle group, but no AE was serious. AEs led to
discontinuation in 1.9% (PERFECT 1) and 1.2%
(PERFECT 2) of the those in the trifarotene cream
and in no patients in the vehicle group; these AEs
were most commonly application site irritation,
allergic dermatitis, and skin irritation. There were
no significant clinically relevant changes in vital
signs, physical examination findings, or laboratory
parameters. There were 4 pregnancies (0.2%) among
the 2420 patients (1 pregnant patient was exposed to
trifarotene cream and 3 were exposed to vehicle
cream). The subject exposed to trifarotene was lost
to follow-up.

DISCUSSION
The 2 large-scale phase III studies generated
independent and substantial evidence of the efficacy and safety of trifarotene cream in moderate
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Fig 2. Truncal acne vulgaris: secondary end points from baseline to week 12. Success rate
according to the Physician’s Global Assessment (PGA) of truncal acne is defined as a PGA score
of 0 or 1 and at least a 2-grade improvement. (intent-to-treat trunk population; multiple
imputation [MI]).

facial and truncal acne. In both anatomic regions
(face and trunk), trifarotene cream was significantly
superior to vehicle in success rates and in reduction
of inflammatory and noninflammatory lesion
counts.
There is sparse literature for the prevalence and
treatment of chest and back acne despite it being a
very common condition. Truncal acne often
accompanies facial acne in adolescence, or it may
first occur in and, indeed, persist well into
adulthood.4 Truncal acne has been estimated to
occur in 56% of patients with acne, with only a
slightly higher predominance in males (55% vs
46%).7 Back acne, once thought to be a
predominantly male disease, has been shown to be
prevalent in females.6
The pathophysiologic mechanism of acne on the
chest and back is similar to that of facial acne and
centers on the physiology and properties of the
pilosebaceous unit.3,4,8 Both anatomic areas are
considered sebum-rich locations, although the

sebaceous follicles on the back have a histologic
appearance different from those on the face.8 Few
studies have evaluated drugs in the treatment of
truncal acne and there are no well-designed
comparative studies. Most studies have been small
in scale and not rigorously controlled.3,4 A review of
the sparse evidence of the treatment outcomes of
acne located in different anatomic regions has shown
varying responses to systemic therapy when the face
and trunk are involved.8 The onset of effect of
trifarotene 50 g/g cream versus that of its vehicle
was rapid, with significant reductions in both
inflammatory and noninflammatory lesion counts
seen as early as 1 week after treatment on the face
and as early as 2 weeks after treatment on the trunk.
This observation is consistent with the findings of a
12-month, long-term safety study of trifarotene
50 g/g cream, in which the success rate for the
face and trunk demonstrated a consistent continuous
clinical improvement over time and within the same
subject (separate analysis).9
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Fig 3. Tolerability profile of trifarotene and vehicle from baseline to week 12 in facial and
truncal acne. Severity scale score indicates: 0 (none), 1 (mild), 2 (moderate) and 3 (severe).

Trifarotene had a manageable safety and tolerability profile, with the majority of AEs being local
cutaneous irritation that began mainly during the first
weeks of treatment and improved thereafter. Local
tolerability was better on the trunk than on the face.
Similar results were reported in a long-term safety
study of trifarotene.9 In the combined pool from both
studies, the local signs and symptoms for the face
and trunk that worsened after baseline (skin dryness,
erythema, scaling, stinging, and burning) were mild
to moderate in severity, with few subjects who
experienced severe tolerability problems. The implementation of routine standard skin care, such as
use of noncomedogenic moisturizers and gentle
cleanser, and dosing regimen adjustments were
sufficient to ensure treatment management and
compliance in the majority of patients. There were
no relevant changes in laboratory safety test results
when trifarotene 50 g/g cream was applied to large
surface areas. Study limitations include absence of
well-established optimal regimens and dosing strategies for truncal acne. These two phase 3 studies
showed that once-daily trifarotene cream appears
effective and safe, with manageable local tolerability,

for the treatment for facial and truncal acne. The
studies provide substantial evidence to support use
of this new topical retinoid in facial and truncal acne.

CONCLUSIONS
Trifarotene 50 g/g cream appears to be effective
and safe in the treatment of moderate acne on the
face and trunk, meeting all primary and secondary
efficacy end points of 2 independent, randomized,
well-controlled studies. Trifarotene exhibited the
expected local tolerability profile of a topical retinoid. In both studies, the local tolerability profile of
trifarotene was mostly mild or moderate and
manageable when it was applied to the face as well
as to the larger body surface areas of the trunk.
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